GlaxoSmithKline also registered Retrovir 300 mg x 60, Retrovir 250 mg x 40 and Trizivir 750 mg x 60 under the Regulation in 2004, but there were no sales under tiered prices of these products in the reporting period.
„GlaxoSmithKline" pagal Reglamentą taip pat užregistravo Retrovir 300 mg x 60, Retrovir 250 mg x 40 ir Trizivir 750 mg x 60, tačiau ataskaitiniu laikotarpiu šie vaistai nebuvo parduodami skirtingomis kainomis.